Combination treatment with cisplatin and schizophyllan for 7,12-dimethylbenz(a)anthracene-induced rat ovarian adenocarcinoma

J Obstet Gynaecol (Tokyo 1995). 1995 Oct;21(5):521-7. doi: 10.1111/j.1447-0756.1995.tb01047.x.

Abstract

Objective: Experimental chemotherapy was conducted to investigate the combined effect of Schizophyllan (SPG) and Cisplatin (CDDP).

Methods: Rats with 7,12-dimethylbenz(a)anthracene (DMBA)-induced ovarian adenocarcinoma received SPG and/or CDDP, were observed for the anti-tumor effect of the drugs and were subjected to immunohistochemical study.

Results: 1) Tumor reduction was enhanced by the combined use of SPG and CDDP; 2) The survival rate of rats given SPG alone was significantly higher than that of the control rats, and treatment with SPG combined with CDDP tended to improve the survival rate; 3) Immunohistochemically, an infiltrative increase in cytotoxic T-lymphocytes (CTL) was induced, although the development of helper T-cells and macrophages was immunohistochemically weak at the tumor site.

Conclusion: The administration of SPG enhanced the anti-tumor effect of CDDP.

MeSH terms

  • 9,10-Dimethyl-1,2-benzanthracene
  • Adenocarcinoma / chemically induced
  • Adenocarcinoma / drug therapy*
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinogens
  • Cisplatin / therapeutic use
  • Female
  • Ovarian Neoplasms / chemically induced
  • Ovarian Neoplasms / drug therapy*
  • Rats
  • Rats, Inbred F344
  • Sizofiran / therapeutic use

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Carcinogens
  • 9,10-Dimethyl-1,2-benzanthracene
  • Sizofiran
  • Cisplatin